Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients

Phase II Study of Autologous Peripheral Blood CD34 Stem Cell Implantation in Chronic Stroke Patients

The objective of the study is to determine the efficacy of brain transplants of CD34+ stem cells obtained from peripheral blood of patients in the treatment of chronic stroke patients.

30 patients are divided into 2 groups, one treatment group and one control group.Treatment group will be implanted with peripheral blood stem cell and receive convention stroke therapy ,and control group only receive convention stroke therapy. We expect that transplantation of the peripheral blood CD34+ cells has the potential of significant benefit to neurological recovery. In a previous phase I clinical trial, we have shown that transplantation of CD34+ cells obtained from the peripheral blood of the chronic stroke patients was safe and beneficial for neurological recovery. We expect this trial can further prove the efficacy of this treatment method.

Inclusion Criteria:

• aged 35-70 chronic stroke adult patient,
• with stroke history of more than 6 months, less than 60 months，
• with stable hemiplegia condition, and
• NIHSS (NIH Stroke Scale) score is between 9-20.

Exclusion Criteria:

• patients aged less than 35 or more than 70,
• hemorrhage stroke or MRI show the occlusion is not in the middle cerebral artery territory，NIHSS is not in the range of 9-20,
• pregnant women,
• impaired liver function, abnormal blood coagulation, AIDS, combine other tumor or special condition.